Real World Reports

BSP real-world data reports provide an in-depth analysis of Electronic Health Record (EHR) or Electronic Medical Record (EMR) data. These reports contain data analysis representing 10% of US hospitals and 16% of the US population with data from over 273 MM patient visits. They include all associated patient diagnoses, treatments, procedures, lab tests and results, and outcomes. Cost of acquiring this type of data is high and requires complex analysis. We provide accurate, cost-effective, and detailed analysis required to make informed decisions. Our reports also include dashboards highlighting usage of key treatments such as share of patients on treatment, profile of treated patients, length of stay, number of doses, cost, and mortality rate.
Our reports serve as a valuable tool with actionable guidance for life-science stakeholders in sales, marketing, and business management. We cover these key aspects of hospital-treated diseases:

  • Patient volumes and segmentation (by severity, demographics, and comorbidity)
  • Admission setting and patient flow through diagnosis
  • Lab tests and empirical therapy
  • Treatment switching based on lab results
  • Length of stay and costs of treatment
  • Outcomes

Our data comes from a broad sample size, including representation across the US, different system sizes, and all patient types.

  • Patient data from in-patient, outpatient, and emergency room settings
  • Lab orders and results, and the changes in therapy prompted by each
  • Costs and outcomes associated with different patient and treatment types

 
REAL-WORLD DATA REPORTS
Save 10% on any report by using promo code: BSPSAVE10

BSP President Attends ISPOR EUROPE 2018 as Presenter and Judge
Barcelona, Spain (November 10-14, 2018) – Boston Strategic Partners, Inc. a global life sciences consulting firm presented at the International Society
Read more.
Medical Communications Consultant
The primary purpose of this position is to support the development of high-quality medical communications. The individual will synthesize key
Read more.
Healthcare Associate
The “Healthcare Associate” at Boston Strategic Partners (BSP) is a support position which will report to various teams and the
Read more.
SAS Data Scientist
Position Description Boston Strategic Partners, Inc. has an immediate opening for a full-time, SAS Data Scientist to join our healthcare
Read more.
Healthcare Consultant
The “Healthcare Consultant” at Boston Strategic Partners will collaborate with various teams and the company leadership. We prefer applicants with
Read more.
Merck CORE Symposium 2018
Philadelphia, PA (June 2018) – Boston Strategic Partners, Inc. was invited to participate in the CORE Global Conference at Merck.
Read more.
Boston Strategic Partners supports poster presentation at the 2017 Annual Meeting of the American Society of Regional Anesthesia and Pain
(Lake Buena Vista, FL, Dec 2017) – Boston Strategic Partners supported Mallinckrodt in the creation of two posters recently presented
Read more.
Highlights from the Regulatory Affairs Professionals Society (RAPS) 2017 Conference
(September 2017): Boston Strategic Partners, Inc. attended the 2017 Regulatory Affairs Professionals Society Convergence held 9-12 September 2017, in Washington
Read more.
BSP supported article, Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings, published in PharmacoEconomics
(Boston,  September 2017) – Boston Strategic Partners supported Baxter in the creation an article recently published in PharmacoEconomics – Open
Read more.
Boston Strategic Partners, Inc. utilizes Electronic Health Record Data to analyze hospital treated sepsis
Boston Strategic Partners, Inc. is utilizing its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to
Read more.
Boston Strategic Partners, Inc. launches Real World Data Reports
We are pleased to announce that Boston Strategic Partners, Inc. (BSP) is utilizing its extensive experience with Health Economics and Outcomes
Read more.
Boston Strategic Partners supports SAGE Therapeutics in the creation of an article titled “Brexanolone (SAGE-547 injection) in post-partum depression: a
(Boston,  June 2017) – Boston Strategic Partners supported SAGE Therapeutics in the creation of an article recently published in The
Read more.
BSP authors seven abstracts for ISPOR, one nominated as a Research Presentation Award Finalist
Boston Strategic Partners, Inc has authored seven abstracts that were accepted to be presented at the ISPOR Conference in Boston
Read more.
Clinical benefits of TA-ER boost quality of life for knee OA patients
Download Poster HERE TITLE: AN INTRA-ARTICULAR, EXTENDED-RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE AS A COST-EFFECTIVE THERAPY FOR TREATING OSTEOARTHRITIS OF THE
Read more.
Cost Savings from Reduced Hospitalizations with Use of Home Noninvasive Ventilation for COPD
March 2017 – Boston Strategic Partners, Inc. co-authored article “Cost Savings from Reduced Hospitalizations with Use of Home Noninvasive Ventilation
Read more.
BSP authored poster wins Poster Award at ISICEM
Boston Strategic Partners, Inc. authored poster “Pulmonary artery catheter (PAC) use is associated with improved clinical outcomes after adult cardiac
Read more.
Burden of illness for super-refractory status epilepticus patients
Beg JM, Anderson TD, Francis K, et al. Burden of illness for super-refractory status epilepticus patients. J Med Econ. 2017;20(1):45-53.
Read more.
The economic impact of poor sample quality in clinical chemistry laboratories: results from a global survey
Erdal EP, Mitra D, Khangulov VS, Church S, Plokhoy E. The economic impact of poor sample quality in clinical chemistry
Read more.
Cost Savings from Reduced Hospitalizations with Use of Home Noninvasive Ventilation for COPD
Coughlin S, Peyerl FW, Munson SH, Ravindranath AJ, Lee-Chiong TL. Cost Savings from Reduced Hospitalizations with Use of Home Noninvasive
Read more.
A Pooled Analysis Evaluating Renal Safety in Placebo- and Active Comparator-Controlled Phase III Trials of Multiple-Dose Injectable HPβCD-Diclofenac in Subjects
Daniels SE, Gan TJT, Hamilton DA, et al. A Pooled Analysis Evaluating Renal Safety in Placebo- and Active Comparator-Controlled Phase
Read more.
Impact of intravenous fluid composition on outcomes in patients with systemic inflammatory response syndrome
Shaw AD, Schermer CR, Lobo DN, Munson SH, Khangulov V, Hayashida D, Kellum JA. Impact of intravenous fluid composition on
Read more.
Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation
Krajewski ML, Raghunathan K, Paluszkiewicz SM, Schermer CR, Shaw AD. Meta-analysis of high- versus low-chloride content in perioperative and critical
Read more.
Clinical and Laboratory Hematologic Findings in Patients Receiving Repeated-Dose Injectable HPBCD-Diclofenac for Acute Postoperative Pain: Pooled Analysis of Two Randomized
Gan, Singla N, Daniels SE, Hamilton DA, Lacouture PG, Johnson O, Reyes CRD, Carr DB, Clinical and Laboratory Hematologic Findings
Read more.
Association between intravenous chloride load during resuscitation and in-hospital mortality among patients with SIRS
Shaw AD, Raghunathan K, Peyerl FW, Munson SH, Paluszkiewicz SM, Schermer CR. Association between intravenous chloride load during resuscitation and
Read more.
Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery:
Daniels S, Melson T, Hamilton DA, Lang E, Carr DB. Analgesic efficacy and safety of a novel injectable formulation of
Read more.
Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo
Carr DB, McDonnell Moorehead T, Bouchard A, et al. Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel
Read more.
Safety of a novel parenteral formulation of diclofenac after major orthopedic or abdominal/pelvic surgery in a population including anticoagulated, elderly
Chelly JE, Singla SK, Melson TI, Lacouture PG, Paadre S, Carr DB. Safety of a novel parenteral formulation of diclofenac
Read more.
Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations
Mermelstein F, Hamilton DA, Wright C, Lacouture PG, Ramaiya A, Carr DB. Single-dose and multiple-dose pharmacokinetics and dose proportionality of
Read more.
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and
Kao DP, Davis G, Aleong R, et al. Effect of bucindolol on heart failure outcomes and heart rate response in
Read more.
A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic
Gan TJ, Daniels SE, Singla N, Hamilton DA, Carr DB. A novel injectable formulation of diclofenac compared with intravenous ketorolac
Read more.
TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis
McKee A, Peyerl F. TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis. Am J Manag Care. 2012;18(1):e1-14.  
Read more.
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms
O’Connor CM, Fiuzat M, Carson PE, et al. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. Stoll
Read more.
Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production
Merrigan M, Venugopal A, Mallozzi M, et al. Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust
Read more.
Putting real options to work to improve Project planning – Project Analysis? Climb the Decision Tree
Date: 9/9/2002 Fabian D’Souza  Putting real options to work to improve Project planning – Project Analysis? Climb the Decision Tree
Read more.
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment
Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Read more.
Pulmonary artery catheter EHR analysis poster accepted to the ISICEM 2017 Conference
//platform.linkedin.com/in.js (February 2017): Boston Strategic Partners, Inc. authored poster “Pulmonary artery catheter (PAC) use is associated with improved clinical outcomes
Read more.
Post-surgery pain poster presented at the 16th World Congress on Pain in Yokohama, Japan
(Yokohama, Japan, September 27, 2016): Boston Strategic Partners Inc. authored poster “Acute pain and related outcomes in surgical patients: retrospective
Read more.
BSP to present at the 16th World Congress on Pain in Yokohama, Japan
//platform.linkedin.com/in.js (Yokohama, Japan, September 26, 2016): Boston Strategic Partners Inc. is attending the 16th World Congress on Pain and will
Read more.
mynewsletter
testing 1234
Read more.
Budget Impact Analysis confirms the critical role of home care in COPD, results revealed at ISPOR 2016
//platform.linkedin.com/in.js (Washington DC, May 25th 2016): Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by airflow limitation and
Read more.
Retrospective analysis of PHN treatment patterns reveals widespread use of opioids, CNS depressants, and polypharmacy
//platform.linkedin.com/in.js (Washington DC, May 24th 2016): Postherpetic Neuralgia (PHN) is a painful condition that can last for months or years,
Read more.
BSP team identifies association between COPD comorbidites and hospital readmissions; results to be released at ISPOR 2016
//platform.linkedin.com/in.js (Washington DC, May 23rd 2016): Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of hospitalizations in older adults,
Read more.
BSP collaborative research exploring economic impact of intravenous fluid choices for cardiac surgery on display at ISPOR 2016 today
//platform.linkedin.com/in.js (Washington DC, May 23rd 2016): Patients undergoing cardiac surgery (CS) routinely receive intravenous (IV) crystalloids perioperatively (during and immediately
Read more.
Explored-1
Read more.
BSP to present at the upcoming ISPOR 2016 Annual Meeting in Washington DC
//platform.linkedin.com/in.js We are excited to share four presentations (three in collaboration) at the upcoming ISPOR 21st Annual Meeting between May
Read more.
BSP co-authored poster investigating PHN treatment patterns wins silver medal at AMCP Annual Meeting 2016
//platform.linkedin.com/in.js San Francisco, CA: Boston Strategic Partners, Inc. (BSP) recently co-authored a poster titled ‘Opioid analgesic use and polypharmacy is
Read more.
Test_Tab
Read more.
Update#2 in the whitepaper series on free speech rights for pharma and med device companies
//platform.linkedin.com/in.js Boston, MA: Boston Strategic Partners, Inc. (BSP) provides the second update in the recently authored white paper series exploring the
Read more.
Business and Clinical Strategy
In a constantly evolving industry, our clients are faced with critical business and clinical choices on a regular basis. We
Read more.
Health Economics and Outcomes Research
In harmony with the evolving scope of health economics and outcomes research, our aim is to enable our clients to
Read more.
Medical Communications
In an increasingly informed digital world, we help our clients develop high impact communications targeted at corporate stakeholders, the scientific
Read more.
Regulatory Strategy
We recognize that regulatory requirements and concerns are intricately woven into product development, launch, and life cycle planning. We provide
Read more.
Financial Advisory
Our team (through Colorado Financial Service Corp.) offers a variety of financial services across the healthcare and life science industries*:
Read more.
Reimbursement Planning
Read more.
BSP authors new whitepaper on implications of free speech rights on off-label marketing and promotion materials for pharma and med
//platform.linkedin.com/in.js Boston, MA: Boston Strategic Partners, Inc. (BSP) provides an update to the recently authored white paper exploring the concept of
Read more.
BSP authors new whitepaper on implications of free speech rights on off-label marketing and promotion materials for pharma and med
//platform.linkedin.com/in.js Boston, MA: Boston Strategic Partners, Inc. (BSP) has recently authored a white paper exploring the concept of free speech
Read more.
BSP collaborative research evaluates the impact of intravenous (IV) fluid composition on outcomes in patients with SIRS
//platform.linkedin.com/in.js Predominant use of 0.9% saline is associated with significantly increased morbidity and mortality as compared to predominant use of
Read more.
BSP Partner Fred Peyerl addresses the 4th International Conference and Exhibition on Surgery in Dubai on October 05th 2015
//platform.linkedin.com/in.js Dubai: Boston Strategic Partners, Inc. (BSP) Partner Fred Peyerl presented a talk on the applications of Electronic Health Record (EHR)
Read more.
BSP delivers talk on Big Data at the American Statistical Association conference
//platform.linkedin.com/in.js Kansas City, Missouri: Boston Strategic Partners, Inc. (BSP) Principal, Victor Khangulov PhD, was invited to present a seminar at
Read more.
BSP team identifies cost savings for hospitals treating SIRS patients; results to be released at ASHP Midyear Clinical Meeting 2014
//platform.linkedin.com/in.js Anaheim, California: Treating systemic inflammatory response syndrome (SIRS) afflicted hospitalized patients with balanced calcium-free intravenous crystalloid solutions (solutions of
Read more.
BSP collaborative meta-analysis identifies association between the use of high-chloride intravenous crystalloid fluids and unfavorable patient outcomes in the perioperative
//platform.linkedin.com/in.js A significant association between the use of high-chloride intravenous crystalloid fluids and unfavorable patient outcomes in the perioperative or
Read more.
BSP President Fabian D'Souza Advises International Seminar at AdvaMed 2014
//platform.linkedin.com/in.js Chicago, Illinois: Boston Strategic Partners, Inc. (BSP) President Fabian D’Souza was invited as a panelist at the recently concluded International
Read more.
BSP collaborative research identifies association between administered intravenous chloride load and in-hospital mortality rate in patients with SIRS
//platform.linkedin.com/in.js Limiting the amount of chloride administered via intravenous fluids to patients with systemic inflammatory response syndrome (SIRS) may lower
Read more.
BSP addresses the biophotonics industry at the Strategies in Biophotonics 2014 Conference
//platform.linkedin.com/in.js Boston, MA: Boston Strategic Partners, Inc. (BSP) executives Dr. Fabian D’Souza, President, Dr. Fred Peyerl, Partner, and Dr. Sibyl
Read more.
Join Physician Panel
(function(i,s,o,g,r,a,m){i=r;i=i||function(){ (i.q=i.q||.l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o);a.async=1;a.src=g;m.parentNode.insertBefore(a,m) })(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’); ga(‘create’, ‘UA-42484266-3’, ‘bostonsp.com’); ga(‘send’, ‘pageview’); #mc_embed_signup{background:#fff; clear:left; font:14px Helvetica,Arial,sans-serif; } /* Add your own MailChimp
Read more.

Contact us at realworldreports@bostonsp.com to request custom reports or for more information on any of our listed reports. We will reply within 48 hours.